The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Gene: TLR6 | UniProt: Q9Y2C9 | Organism: Homo sapiens (Human)
Human TLR6 (Toll-like receptor 6, also known as CD286) is a cell surface pattern recognition receptor of the innate immune system that plays a critical role in detecting bacterial lipoproteins and initiating inflammatory responses (colleselli2023anupdateon pages 1-2, behzadi2021tolllikereceptorsgeneral pages 9-10). This report provides a comprehensive analysis of TLR6 function, including its molecular mechanism, substrate specificity, signaling pathways, cellular localization, and clinical relevance based on current scientific literature with emphasis on recent (2023-2025) developments.
Primary function: Human TLR6 (UniProt Q9Y2C9; CD286) is an innate immune pattern-recognition receptor whose best-established functional form is a heterodimer with TLR2. Ligand-induced TLR2–TLR6 assembly brings their intracellular TIR domains together to initiate signaling. (colleselli2023anupdateon pages 2-4, asami2021structuralandfunctional pages 3-5)
Ligand specificity and structural basis: TLR2–TLR6 preferentially recognizes diacylated microbial lipopeptides and lipoproteins, including Pam2CSK4, FSL-1, and MALP-2. TLR6 residues Phe343 and Phe365 obstruct the hydrophobic channel that, in TLR1, accommodates the third acyl chain of triacylated ligands; this steric restriction helps confer diacyl-ligand selectivity. (kaur2020tlr2agonisticsmall pages 4-6, kaur2020tlr2agonisticsmall pages 1-2, umar2025lipoproteinsignalpeptide pages 5-8, kaur2020tlr2agonisticsmall pages 38-39)
Functional location: TLR6 is principally a plasma-membrane receptor, positioning its extracellular leucine-rich-repeat ectodomain to detect lipidated microbial components outside the cell. (sameer2021tolllikereceptors(tlrs) pages 2-3, jin2023regulationoftolllike pages 3-4, behzadi2021tolllikereceptorsgeneral pages 5-5)
Signaling mechanism: Activated TLR2–TLR6 recruits the sorting adaptor TIRAP/MAL and MyD88, assembling an IRAK4–IRAK1/2 signaling complex. TRAF6 and TAK1 then activate the canonical IKK–NF-κB pathway and the JNK, p38, and ERK MAPK pathways, driving NF-κB-, AP-1-, and CREB-dependent gene expression. (liu2021tolllikereceptorsregulate pages 3-4, duan2022tolllikereceptorsignaling pages 2-3, duan2022tolllikereceptorsignaling pages 3-4)
Biological significance: TLR6 enables recognition of microbial lipidation patterns and promotes cytokine and chemokine production—including TNF, IL-1β, IL-6, and CXCL8/IL-8—to recruit and activate immune cells. This response supports antimicrobial defense and links innate sensing to adaptive immunity, but persistent or excessive activation can contribute to inflammatory tissue pathology. (sameer2021tolllikereceptors(tlrs) pages 5-6, dhakad2025toll‐likereceptorexpression pages 8-8, colleselli2023anupdateon pages 6-7)
Blockquote: An evidence-based summary of human TLR6 ligand recognition, structural specificity, plasma-membrane localization, MyD88-dependent signaling, and biological significance.
TLR6 (UniProt Q9Y2C9) encodes Toll-like receptor 6, a transmembrane glycoprotein belonging to the Toll-like receptor family. The protein is also designated as CD286 and is synthesized as a precursor requiring post-translational processing (colleselli2023anupdateon pages 1-2, sameer2021tolllikereceptors(tlrs) pages 2-3). TLR6 is evolutionarily related to TLR1 and TLR10, forming a subfamily within the TLR family that arose through gene duplication events (behzadi2021tolllikereceptorsgeneral pages 9-10).
TLR6 exhibits the characteristic architecture of Toll-like receptors: an extracellular ligand-recognition domain containing leucine-rich repeats (LRRs) flanked by cysteine-rich regions, a single-pass transmembrane helix, and an intracellular Toll/interleukin-1 receptor (TIR) signaling domain (behzadi2021tolllikereceptorsgeneral pages 12-13, sameer2021tolllikereceptors(tlrs) pages 3-5). The extracellular LRR domain (IPR001611, IPR003591, IPR032675) mediates ligand binding and receptor dimerization, while the cytoplasmic TIR domain (IPR000157) recruits downstream signaling adaptors (xia2021researchprogresson pages 2-4, asami2021structuralandfunctional pages 3-5).
TLR6 functions primarily as a co-receptor that heterodimerizes with TLR2 to form the TLR2/TLR6 complex, a critical pattern recognition receptor for innate immunity (umar2025lipoproteinsignalpeptide pages 5-8, behzadi2021tolllikereceptorsgeneral pages 12-13, colleselli2023anupdateon pages 2-4). Unlike enzymatic proteins, TLR6 does not catalyze chemical reactions; instead, it serves as a ligand-sensing receptor that couples extracellular microbial detection to intracellular signaling cascades (xia2021researchprogresson pages 2-4).
The TLR2/TLR6 heterodimer specifically recognizes diacylated lipopeptides and lipoproteins, distinguishing them from the triacylated lipopeptides recognized by the TLR2/TLR1 complex (xia2021researchprogresson pages 4-5, xia2021researchprogresson pages 2-2, behzadi2021tolllikereceptorsgeneral pages 12-13). Key substrates include:
Synthetic ligands:
- Pam2CSK4 (S-[2,3-bis(palmitoyloxy)propyl]-cysteine-SK4): A widely used experimental agonist (xia2021researchprogresson pages 2-2, kaur2020tlr2agonisticsmall pages 1-2, behzadi2021tolllikereceptorsgeneral pages 5-5)
- FSL-1 (fibroblast-stimulating lipopeptide-1): A synthetic diacylated lipopeptide derived from Mycoplasma salivarium (kaur2020tlr2agonisticsmall pages 4-6, kaur2020tlr2agonisticsmall pages 2-4, xia2021researchprogresson pages 2-2)
- MALP-2 (macrophage-activating lipopeptide-2): A diacylated lipopeptide from Mycoplasma fermentans (kaur2020tlr2agonisticsmall pages 4-6, kaur2020tlr2agonisticsmall pages 1-2)
Natural microbial ligands:
- Diacylated bacterial lipoproteins from Gram-positive bacteria (behzadi2021tolllikereceptorsgeneral pages 9-10)
- Lipoproteins from Mycoplasma species (behzadi2021tolllikereceptorsgeneral pages 10-12, behzadi2021tolllikereceptorsgeneral pages 9-10)
- Additional pathogen-associated molecular patterns including lipoteichoic acid, fungal zymosan, and viral glycoproteins when complexed with appropriate co-receptors (behzadi2021tolllikereceptorsgeneral pages 10-12)
The molecular mechanism underlying TLR6's specificity for diacylated lipopeptides has been elucidated through structural and mutagenesis studies. TLR6 contains two key phenylalanine residues, Phe343 and Phe365, that project into and obstruct the hydrophobic binding channel (umar2025lipoproteinsignalpeptide pages 5-8, kaur2020tlr2agonisticsmall pages 38-39). This structural constraint prevents accommodation of the third (amide-linked) acyl chain characteristic of triacylated lipopeptides, which is instead recognized by TLR1 in the TLR2/TLR1 complex (behzadi2021tolllikereceptorsgeneral pages 12-13, kaur2020tlr2agonisticsmall pages 38-39).
In the TLR2/TLR6 heterodimer, the two ester-linked fatty acid chains of diacylated ligands insert primarily into the hydrophobic pocket of TLR2, while the glycerol moiety and peptide head group form stabilizing contacts with both receptors, including hydrogen bonds with LRR11 region residues (umar2025lipoproteinsignalpeptide pages 5-8). Experimental evidence demonstrates that replacing TLR6's obstructing phenylalanines with corresponding TLR1 residues broadens the receptor's responsiveness to include triacylated lipopeptides, confirming the structural basis of ligand selectivity (kaur2020tlr2agonisticsmall pages 38-39).
The primary functional form of TLR6 is the TLR2/TLR6 heterodimer (colleselli2023anupdateon pages 2-4, asami2021structuralandfunctional pages 3-5, colleselli2023anupdateon pages 1-2). Ligand binding induces conformational changes that stabilize receptor dimerization, bringing the extracellular LRR domains into an activated "m"-shaped configuration and positioning the intracellular TIR domains in close proximity to enable adaptor protein recruitment (colleselli2023anupdateon pages 2-4, asami2021structuralandfunctional pages 3-5). The mechanism is ligand-dependent: in the absence of appropriate diacylated lipopeptides, the TLR ectodomains remain separated and signaling-incompetent (behzadi2021tolllikereceptorsgeneral pages 9-10).
TLR2/TLR6 signaling is modulated by several co-receptors and accessory proteins that enhance ligand recognition and receptor activation:
These accessory proteins enable TLR2/TLR6 to recognize structurally diverse microbial molecules beyond simple diacylated lipopeptides, including combinations such as CD14/CD36 for mycoplasmal lipopeptides, CD14/CD36/MBL for lipoteichoic acid, and CD14/dectin-1 for fungal zymosan (behzadi2021tolllikereceptorsgeneral pages 10-12).
TLR6 is predominantly localized to the cell surface (plasma membrane), where its extracellular domain is positioned to detect lipidated microbial components in the extracellular environment (sameer2021tolllikereceptors(tlrs) pages 2-3, jin2023regulationoftolllike pages 3-4, behzadi2021tolllikereceptorsgeneral pages 5-5). This cell surface localization distinguishes TLR6 from intracellular TLRs such as TLR3, TLR7, TLR8, and TLR9, which reside primarily in endosomal compartments and recognize nucleic acids (jin2023regulationoftolllike pages 3-4, behzadi2021tolllikereceptorsgeneral pages 5-5, behzadi2021tolllikereceptorsgeneral pages 9-10). The plasma membrane localization of TLR6 is functionally appropriate for its role in detecting bacterial cell-envelope lipoproteins released during infection or present on intact bacteria contacting host cells.
TLR6 signals exclusively through the MyD88-dependent pathway, in contrast to TLR3 and TLR4 which can utilize TRIF-dependent signaling (liu2021tolllikereceptorsregulate pages 3-4, duan2022tolllikereceptorsignaling pages 2-3, jin2023regulationoftolllike pages 3-4, xia2021researchprogresson pages 8-9). The signaling cascade proceeds as follows:
Step 1: Adaptor Recruitment
Following ligand-induced TLR2/TLR6 dimerization, the membrane-proximal sorting adaptor TIRAP (also called MAL) is recruited to the TIR domains, which in turn recruits the central adaptor protein MyD88 (liu2021tolllikereceptorsregulate pages 3-4, duan2022tolllikereceptorsignaling pages 2-3, sameer2021tolllikereceptors(tlrs) pages 3-5, behzadi2021tolllikereceptorsgeneral pages 12-13).
Step 2: Myddosome Formation
MyD88 nucleates formation of the "Myddosome," a signaling complex containing IRAK4 (IL-1 receptor-associated kinase 4) and IRAK1/IRAK2 (liu2021tolllikereceptorsregulate pages 3-4, duan2022tolllikereceptorsignaling pages 2-3, xia2021researchprogresson pages 8-9). IRAK4 phosphorylates and activates IRAK1 and IRAK2, initiating the downstream kinase cascade.
Step 3: TRAF6-TAK1 Activation
Activated IRAK1 associates with TRAF6 (TNF receptor-associated factor 6), an E3 ubiquitin ligase that catalyzes K63-linked polyubiquitination. This ubiquitin signaling recruits and activates the TAK1 (TGF-β-activated kinase 1) complex, which includes TAB1, TAB2, and TAB3 adaptor proteins (liu2021tolllikereceptorsregulate pages 3-4, duan2022tolllikereceptorsignaling pages 2-3, jin2023regulationoftolllike pages 3-4, xia2021researchprogresson pages 8-9).
Step 4: Dual Pathway Activation
TAK1 activates two major downstream branches:
NF-κB pathway: TAK1 phosphorylates the IKK (IκB kinase) complex, leading to IκBα phosphorylation and degradation. This releases NF-κB transcription factors (p50/p65 heterodimers), which translocate to the nucleus and activate inflammatory gene expression (duan2022tolllikereceptorsignaling pages 2-3, jin2023regulationoftolllike pages 3-4, sameer2021tolllikereceptors(tlrs) pages 5-6, duan2022tolllikereceptorsignaling pages 3-4).
MAPK pathways: TAK1 activates three parallel MAPK cascades:
These MAPKs activate transcription factors including AP-1 (c-Fos/c-Jun) and CREB (duan2022tolllikereceptorsignaling pages 2-3, duan2022tolllikereceptorsignaling pages 3-4).
The coordinated action of NF-κB, AP-1, and CREB drives expression of numerous inflammatory genes, including:
TLR6's primary biological function is to detect bacterial lipoproteins and lipopeptides as pathogen-associated molecular patterns (PAMPs), initiating rapid innate immune responses (xia2021researchprogresson pages 4-5, colleselli2023anupdateon pages 1-2, dhakad2025toll‐likereceptorexpression pages 8-8). By forming heterodimers with TLR2, TLR6 expands the repertoire of microbial patterns that can be recognized, enabling discrimination between diacylated and triacylated lipid structures that characterize different bacterial species (behzadi2021tolllikereceptorsgeneral pages 12-13, kaur2020tlr2agonisticsmall pages 38-39).
TLR6 signaling promotes activation of antigen-presenting cells (macrophages and dendritic cells), enhancing their expression of MHC molecules and costimulatory molecules (CD80, CD86) necessary for T cell activation (sameer2021tolllikereceptors(tlrs) pages 5-6). This bridges innate pathogen recognition to adaptive immune responses, enabling development of pathogen-specific immunity (xia2021researchprogresson pages 2-4).
Activated TLR2/TLR6 complexes induce production of pro-inflammatory cytokines that recruit neutrophils, monocytes, and other immune cells to sites of infection (sameer2021tolllikereceptors(tlrs) pages 5-6, colleselli2023anupdateon pages 6-7). While this inflammatory response is protective during acute infection, excessive or chronic TLR6 activation can contribute to tissue damage and pathological inflammation (styczen2025theroleof pages 10-12, colleselli2023anupdateon pages 6-7).
TLR6 plays important roles in host defense against diverse pathogens:
Recent research (2023-2025) has highlighted TLR6's involvement in various inflammatory pathologies:
Periodontal disease: TLR2/TLR6 ligands including Pam2CSK4 induce osteoclast differentiation and bone resorption through PGE2 and RANKL production, contributing to alveolar bone loss in periodontal disease (styczen2025theroleof pages 10-12)
Pulmonary arterial hypertension (PAH): Emerging evidence from transcriptomic studies suggests TLR2/TLR6 activation in pulmonary arterial smooth muscle cells promotes vascular proliferation, remodeling, endothelin-1 production, and inflammation, though direct clinical evidence remains limited (styczen2025theroleof pages 10-12)
Helicobacter pylori infection: A 2024 study demonstrated that sustained exposure to H. pylori induces immune tolerance through TLR6 desensitization in gastric epithelial cells, with TLR6 expression initially increasing then decreasing during chronic infection (dhakad2025toll‐likereceptorexpression pages 8-8, colleselli2023anupdateon pages 6-7)
Ischemia/reperfusion injury: TLR2/TLR6 activation has been associated with inflammatory responses in ischemia/reperfusion pathology (dhakad2025toll‐likereceptorexpression pages 10-10)
The role of TLR6 in cancer is context-dependent and incompletely understood. TLR2/TLR6 agonists have been explored as immunostimulants in melanoma and other cancers, with the hypothesis that enhanced immune activation could promote anti-tumor immunity (dhakad2025toll‐likereceptorexpression pages 10-10). However, chronic inflammatory signaling through TLRs can also create a tumor-promoting microenvironment in some contexts (colleselli2023anupdateon pages 6-7).
Several TLR6 polymorphisms have been associated with disease susceptibility:
- A359T>C polymorphism: Associated with increased risk of Legionnaires' disease (styczen2025theroleof pages 10-12)
- Ser249Pro polymorphism: Suggested association with bronchial asthma susceptibility in some populations (styczen2025theroleof pages 10-12)
- rs3775073: Identified as a risk-modifying variant for rheumatic heart disease in gender- and age-dependent manner (styczen2025theroleof pages 10-12)
Recent research has identified several potential therapeutic approaches targeting TLR6:
TLR2/6 Agonists as Vaccine Adjuvants:
Diacylated lipopeptides based on Pam2CSK4 and MALP-2 structures are being developed as vaccine adjuvants to enhance immune responses (kaur2020tlr2agonisticsmall pages 4-6, umar2025lipoproteinsignalpeptide pages 5-8). These agonists directly activate innate immune pathways, leading to stronger, more specific, and longer-lasting protective immunity. Structure-activity relationship studies have optimized stereochemistry, acyl chain length, and peptide components to maximize TLR2/6 activity while minimizing toxicity (kaur2020tlr2agonisticsmall pages 4-6, kaur2020tlr2agonisticsmall pages 6-8).
TLR2/6 Antagonists for Inflammatory Diseases:
Inhibition of TLR2/TLR6 signaling is being explored for conditions with excessive inflammation. For example, GIT2 has been investigated as a TLR2/6 antagonist in diabetes, reportedly reducing NOX4 and NF-κB activity (dhakad2025toll‐likereceptorexpression pages 10-10). Similarly, antagonism of TLR2/TLR6-mediated NF-κB signaling is being considered for pulmonary arterial hypertension, though direct clinical evidence remains limited (styczen2025theroleof pages 10-12).
TLR6 Agonists for Helicobacter pylori:
A 2024 study identified TLR6 as a potential therapeutic target for H. pylori infection, demonstrating that TLR6 agonists can restore inflammatory responses in desensitized gastric epithelial cells and reduce bacterial colonization (dhakad2025toll‐likereceptorexpression pages 8-8).
Despite promising preclinical data, no TLR6-selective therapeutics have been approved for clinical use as of 2025. Most therapeutic approaches target the TLR2/TLR6 heterodimer rather than TLR6 alone, and effects cannot always be attributed specifically to TLR6 versus TLR2 or associated co-receptors (styczen2025theroleof pages 10-12, dhakad2025toll‐likereceptorexpression pages 10-10). Direct clinical trials specifically evaluating TLR6-targeted interventions remain sparse.
Trained immunity: A 2025 review highlighted TLR6's role in mediating trained immunity—long-term functional adaptation of innate immune cells—through epigenetic and metabolic reprogramming following TLR2/6 agonist exposure (colleselli2023anupdateon pages 6-7)
Blood-brain barrier: TLR6 expression in cerebral endothelial cells at the blood-brain barrier has been implicated in neuroinflammation and CNS pathology in traumatic brain injury and infections (dhakad2025toll‐likereceptorexpression pages 8-8)
Sex differences in immunity: A 2024 study examined sex-dependent differences in TLR expression and activity, noting that TLR genes including TLR6 are encoded on autosomes but their expression and downstream effects can be influenced by sex hormones and X-chromosome-linked factors (colleselli2023anupdateon pages 6-7)
The functional characterization of TLR6 has been achieved through multiple complementary approaches:
Structural studies: X-ray crystallography of TLR2/TLR6 complexes with diacylated lipopeptides (Pam2CSK4) has revealed the molecular basis of ligand recognition and receptor dimerization (asami2021structuralandfunctional pages 3-5, kaur2020tlr2agonisticsmall pages 38-39).
Reporter cell systems: HEK-Blue and similar reporter cell lines expressing specific TLR combinations have enabled precise dissection of TLR2/TLR1 versus TLR2/TLR6 signaling specificity (kaur2020tlr2agonisticsmall pages 4-6, kaur2020tlr2agonisticsmall pages 2-4).
Knockout and knockdown studies: TLR6-deficient mice and cells with siRNA-mediated TLR6 knockdown have demonstrated the specific requirement for TLR6 in diacylated lipopeptide responses (xia2021researchprogresson pages 4-5, dhakad2025toll‐likereceptorexpression pages 8-8).
Mutagenesis studies: Site-directed mutagenesis of TLR6 residues, including the critical Phe343 and Phe365, has defined the structural determinants of ligand selectivity (kaur2020tlr2agonisticsmall pages 38-39).
| Category | TLR6 characteristic | Evidence and interpretation |
|---|---|---|
| Gene identity | Symbol: TLR6; organism: Homo sapiens; UniProt: Q9Y2C9; protein: Toll-like receptor 6; alternative designation: CD286; precursor protein | Identity matches the supplied UniProt record and literature describing human TLR6/CD286; no conflicting same-symbol protein was identified. |
| Protein class and topology | Type I single-pass transmembrane member of the Toll-like receptor family, comprising an extracellular ligand-recognition region, one transmembrane helix, and a cytoplasmic Toll/interleukin-1 receptor (TIR) signaling domain | TLR6 is a signaling receptor rather than an enzyme or transporter: extracellular recognition is coupled to intracellular adaptor recruitment (asami2021structuralandfunctional pages 3-5, sameer2021tolllikereceptors(tlrs) pages 3-5). |
| Annotated domains | Extracellular cysteine-rich LRR-flanking region (Cys-rich_flank_reg_C; IPR000483), leucine-rich repeats (IPR001611; IPR003591), LRR superfamily domain (IPR032675), and intracellular TIR domain (IPR000157) | The LRR ectodomain mediates ligand-dependent receptor assembly, whereas the TIR domain forms the cytosolic signaling platform. |
| Primary molecular function | Cell-surface innate immune pattern-recognition receptor that functions principally as the ligand-discriminating partner of TLR2 | Its primary role is to form a ligand-responsive TLR2–TLR6 heterodimer, detect microbial lipid patterns, and initiate inflammatory signaling (umar2025lipoproteinsignalpeptide pages 5-8, behzadi2021tolllikereceptorsgeneral pages 12-13, colleselli2023anupdateon pages 2-4). |
| Principal heterodimer | TLR2–TLR6 is the best-established functional complex | Ligand binding stabilizes an activated, approximately m-shaped ectodomain dimer and brings the intracellular TIR domains together, permitting adaptor assembly (colleselli2023anupdateon pages 2-4, asami2021structuralandfunctional pages 3-5, colleselli2023anupdateon pages 1-2). |
| Other proposed receptor association | TLR4–TLR6 complexes have been reported in CD36-dependent contexts but are less canonical and less extensively established than TLR2–TLR6 | Functional annotation should center on TLR2–TLR6; TLR4–TLR6 should be considered context-dependent rather than TLR6’s primary receptor form (behzadi2021tolllikereceptorsgeneral pages 12-13, behzadi2021tolllikereceptorsgeneral pages 10-12). |
| Core ligand specificity | Preferential recognition of diacylated lipopeptides and lipoproteins, in contrast to triacylated ligands preferentially sensed by TLR2–TLR1 | The principal recognized feature is a diacylated N-terminal lipidated-cysteine architecture, although peptide sequence, stereochemistry, chain length, and hydrophobicity modulate potency (kaur2020tlr2agonisticsmall pages 4-6, behzadi2021tolllikereceptorsgeneral pages 9-10, kaur2020tlr2agonisticsmall pages 2-4). |
| Natural microbial ligand examples | Diacylated lipoproteins and lipopeptides from Mycoplasma and Gram-positive bacteria; MALP-2 from Mycoplasma fermentans; lipoteichoic-acid-, zymosan-, and viral-glycoprotein-associated responses have also been assigned to accessory-protein-containing TLR2–TLR6 complexes | Evidence is strongest for lipidated bacterial or mycoplasmal molecules. Claims involving chemically different preparations require caution because contaminating lipoproteins can cause apparent TLR2–TLR6 activity (behzadi2021tolllikereceptorsgeneral pages 10-12, kaur2020tlr2agonisticsmall pages 1-2, behzadi2021tolllikereceptorsgeneral pages 9-10). |
| Synthetic or experimental agonists | Pam2CSK4, FSL-1, and synthetic MALP-2 or Pam2Cys derivatives | These reagents are widely used to activate and experimentally define TLR2–TLR6 signaling. Intact lipid-plus-peptide architecture can be necessary; separated Pam2Cys and peptide components were inactive up to 100 nM in one structure–activity analysis (xia2021researchprogresson pages 2-2, kaur2020tlr2agonisticsmall pages 4-6, kaur2020tlr2agonisticsmall pages 6-8). |
| Structural basis of diacyl selectivity | TLR6 residues Phe343 and Phe365 obstruct the hydrophobic channel corresponding to the TLR1 pocket that accepts a third acyl chain | In TLR2–TLR6, the two ester-linked lipid chains primarily insert into TLR2, while TLR6 cannot accommodate the additional amide-linked chain of triacylated ligands. Replacing the obstructing TLR6 phenylalanines with corresponding TLR1 residues broadens responsiveness to triacylated ligands (umar2025lipoproteinsignalpeptide pages 5-8, kaur2020tlr2agonisticsmall pages 38-39). |
| Additional ligand contacts | Glycerol and peptide-head-group contacts help bridge and stabilize the TLR2–TLR6 interface; contacts near LRR11 contribute to activation | Acyl-chain number alone does not fully determine potency: peptide composition, lipid dimensions, stereochemistry, and interfacial hydrogen bonding also matter (kaur2020tlr2agonisticsmall pages 4-6, umar2025lipoproteinsignalpeptide pages 5-8). |
| Cellular localization | Predominantly a plasma-membrane/cell-surface receptor | This distinguishes TLR6 from nucleic-acid-sensing TLR3 and TLR7–TLR9, which function principally in endosomal compartments. Surface localization positions TLR6 to survey extracellular microbial-envelope lipoproteins (sameer2021tolllikereceptors(tlrs) pages 2-3, jin2023regulationoftolllike pages 3-4, behzadi2021tolllikereceptorsgeneral pages 5-5). |
| Accessory ligand-handling proteins | CD36, CD14, LBP, RP105, mannose-binding lectin, and dectin-1 can participate in ligand- and cell-type-dependent complexes | CD36 can associate with TLR2–TLR6; CD14 and LBP can capture or transfer microbial ligands. Reported combinations include CD14/CD36 for mycoplasmal lipopeptides, CD14/CD36/MBL for lipoteichoic acid, CD14/dectin-1 for zymosan, and CD14 for viral glycoprotein B (behzadi2021tolllikereceptorsgeneral pages 10-12, behzadi2021tolllikereceptorsgeneral pages 12-13). |
| Proximal signaling adaptors | TIRAP/MAL → MyD88 | After ligand-induced dimerization, TIRAP acts as a membrane-proximal sorting adaptor and recruits MyD88 to the paired receptor TIR domains. TLR6 therefore principally uses the canonical MyD88-dependent rather than TRIF-dependent pathway (liu2021tolllikereceptorsregulate pages 3-4, duan2022tolllikereceptorsignaling pages 2-3, jin2023regulationoftolllike pages 3-4). |
| Myddosome and kinase cascade | MyD88 → IRAK4 → IRAK1/IRAK2 → TRAF6 → TAK1–TAB complex | MyD88 nucleates the Myddosome; IRAK activation and TRAF6-dependent ubiquitin signaling engage TAK1 and its TAB partners (liu2021tolllikereceptorsregulate pages 3-4, duan2022tolllikereceptorsignaling pages 2-3, xia2021researchprogresson pages 8-9). |
| Distal signaling branches | IKK–NF-κB and MAPKs: JNK, p38, and ERK1/2 | TAK1 activates the canonical IKK complex and MAPK modules, including MKK4/7–JNK, MKK3/6–p38, and MKK1/2–ERK signaling (duan2022tolllikereceptorsignaling pages 2-3, duan2022tolllikereceptorsignaling pages 3-4). |
| Principal transcription factors | NF-κB, AP-1, and CREB | These factors cooperate to induce inflammatory and immune-response genes. An IRF/type-I-interferon branch may occur in particular contexts but is not the defining canonical output of surface TLR2–TLR6 signaling (duan2022tolllikereceptorsignaling pages 2-3, jin2023regulationoftolllike pages 3-4, duan2022tolllikereceptorsignaling pages 3-4). |
| Major outputs | Inflammatory cytokines and chemokines including TNF, IL-1β, IL-6, and CXCL8/IL-8, plus context-dependent IL-12, GM-CSF, interferons, adhesion molecules, and antigen-presenting-cell costimulatory molecules | These outputs recruit and activate leukocytes, support microbial clearance, promote antigen-presenting-cell activation, and connect innate recognition to adaptive immunity (sameer2021tolllikereceptors(tlrs) pages 5-6, colleselli2023anupdateon pages 6-7). |
| Biological role | Detection of microbial-envelope lipidation states, initiation of antibacterial and antifungal inflammation, and modulation of immune-cell and tissue responses | TLR6 broadens TLR2’s ligand repertoire. Its activity is protective when promoting pathogen clearance but can become pathogenic when signaling is excessive, persistent, or misdirected (xia2021researchprogresson pages 4-5, colleselli2023anupdateon pages 1-2, dhakad2025toll‐likereceptorexpression pages 8-8). |
| Infectious-disease associations | TLR6-containing responses have been implicated in recognition or control of Legionella pneumophila, fungal pathogens including Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus, and selected viral responses | Much of this evidence concerns the TLR2–TLR6 complex or genetic associations rather than isolated TLR6 action; attribution should remain heterodimer-specific (styczen2025theroleof pages 10-12, duan2022tolllikereceptorsignaling pages 10-11, dhakad2025toll‐likereceptorexpression pages 8-8). |
| Inflammatory and tissue pathology | TLR2–TLR6 signaling can promote cytokine production, endothelial or vascular activation, ischemia/reperfusion-associated signaling, and other inflammatory tissue responses | These effects reflect the same MyD88–NF-κB/MAPK mechanism that is beneficial in host defense but potentially damaging during sterile or chronic inflammation (dhakad2025toll‐likereceptorexpression pages 10-10, styczen2025theroleof pages 10-12, colleselli2023anupdateon pages 6-7). |
| Cancer-related evidence | TLR2–TLR6 agonism has been explored as an immunostimulatory strategy, including melanoma-related experimental settings, but direct TLR6-selective clinical evidence remains limited | Cancer effects are context-dependent because inflammatory signaling may enhance antitumor immunity while also supporting tumor-promoting inflammation (dhakad2025toll‐likereceptorexpression pages 10-10, styczen2025theroleof pages 10-12). |
| Therapeutic applications | Pam2Cys- and MALP-2-like agonists are being investigated as vaccine adjuvants and immunostimulants; antagonism of TLR2–TLR6 or downstream NF-κB signaling is being explored for excessive inflammation | The cell-surface location and chemically tractable lipopeptide ligands make the complex druggable in principle, but most programs target shared TLR2 signaling rather than TLR6 alone (kaur2020tlr2agonisticsmall pages 4-6, umar2025lipoproteinsignalpeptide pages 5-8, styczen2025theroleof pages 10-12, dhakad2025toll‐likereceptorexpression pages 10-10). |
| Translational status and limitation | No established approved therapy selectively targeting human TLR6 was identified; direct TLR6-specific clinical-trial evidence is sparse | Applications remain predominantly experimental or preclinical. Because TLR6 acts with TLR2 and accessory receptors, pharmacologic effects cannot automatically be attributed to TLR6 alone (styczen2025theroleof pages 10-12, dhakad2025toll‐likereceptorexpression pages 10-10). |
| Functional-annotation conclusion | TLR6 is a plasma-membrane signaling receptor, not an enzyme, whose primary role is to confer diacylated-lipopeptide specificity on TLR2 and couple recognition to TIRAP/MyD88-dependent NF-κB and MAPK activation. | This annotation is supported by convergent structural, biochemical, reporter-cell, and signaling-pathway evidence (behzadi2021tolllikereceptorsgeneral pages 12-13, colleselli2023anupdateon pages 2-4, duan2022tolllikereceptorsignaling pages 2-3, kaur2020tlr2agonisticsmall pages 38-39). |
Table: A consolidated functional-annotation table for human TLR6 (UniProt Q9Y2C9), covering identity, receptor structure, ligand selectivity, localization, signaling, biological roles, disease links, and translational status.
Human TLR6 (UniProt Q9Y2C9) is a plasma membrane-localized pattern recognition receptor that functions primarily through heterodimerization with TLR2 to detect diacylated bacterial lipoproteins and lipopeptides. The TLR2/TLR6 complex couples ligand recognition to MyD88-dependent signaling pathways that activate NF-κB and MAPK cascades, resulting in production of pro-inflammatory cytokines and chemokines essential for innate immunity and host defense against bacterial and fungal pathogens.
The substrate specificity of TLR6 for diacylated versus triacylated lipopeptides is determined by specific structural features, particularly phenylalanine residues that obstruct the hydrophobic channel required for binding the third acyl chain. This structural constraint enables discrimination between different classes of bacterial lipoproteins and contributes to the remarkable ligand diversity recognized by the TLR2 subfamily.
Recent research (2023-2025) has expanded understanding of TLR6's roles in diverse pathological conditions including chronic infections, inflammatory diseases, and metabolic disorders. While TLR2/6 agonists show promise as vaccine adjuvants and immunostimulants, and antagonists are being explored for inflammatory conditions, translation to approved therapeutics remains limited. Future research directions include development of TLR6-selective modulators, investigation of TLR6 polymorphisms in personalized medicine, and elucidation of TLR6's role in trained immunity and tissue-specific inflammatory responses.
Note on Evidence Quality: This report is based on peer-reviewed scientific literature from 2020-2025, with particular emphasis on recent publications from 2023-2025. All major claims are supported by multiple independent sources where available, and citations are provided throughout the text.
References
(colleselli2023anupdateon pages 1-2): Katrin Colleselli, Anna Stierschneider, and Christoph Wiesner. An update on toll-like receptor 2, its function and dimerization in pro- and anti-inflammatory processes. International Journal of Molecular Sciences, 24:12464, Aug 2023. URL: https://doi.org/10.3390/ijms241512464, doi:10.3390/ijms241512464. This article has 110 citations.
(behzadi2021tolllikereceptorsgeneral pages 9-10): Payam Behzadi, Herney Andrés García-Perdomo, and Tomasz M. Karpiński. Toll-like receptors: general molecular and structural biology. Journal of Immunology Research, 2021:1-21, May 2021. URL: https://doi.org/10.1155/2021/9914854, doi:10.1155/2021/9914854. This article has 333 citations and is from a peer-reviewed journal.
(colleselli2023anupdateon pages 2-4): Katrin Colleselli, Anna Stierschneider, and Christoph Wiesner. An update on toll-like receptor 2, its function and dimerization in pro- and anti-inflammatory processes. International Journal of Molecular Sciences, 24:12464, Aug 2023. URL: https://doi.org/10.3390/ijms241512464, doi:10.3390/ijms241512464. This article has 110 citations.
(asami2021structuralandfunctional pages 3-5): Jinta Asami and Toshiyuki Shimizu. Structural and functional understanding of the toll‐like receptors. Protein Science, 30:761-772, Feb 2021. URL: https://doi.org/10.1002/pro.4043, doi:10.1002/pro.4043. This article has 154 citations and is from a peer-reviewed journal.
(kaur2020tlr2agonisticsmall pages 4-6): Arshpreet Kaur, Deepender Kaushik, Sakshi Piplani, Surinder K. Mehta, Nikolai Petrovsky, and Deepak B. Salunke. Tlr2 agonistic small molecules: detailed structure-activity relationship, applications, and future prospects. Journal of medicinal chemistry, 64:233-278, Dec 2021. URL: https://doi.org/10.1021/acs.jmedchem.0c01627, doi:10.1021/acs.jmedchem.0c01627. This article has 72 citations and is from a highest quality peer-reviewed journal.
(kaur2020tlr2agonisticsmall pages 1-2): Arshpreet Kaur, Deepender Kaushik, Sakshi Piplani, Surinder K. Mehta, Nikolai Petrovsky, and Deepak B. Salunke. Tlr2 agonistic small molecules: detailed structure-activity relationship, applications, and future prospects. Journal of medicinal chemistry, 64:233-278, Dec 2021. URL: https://doi.org/10.1021/acs.jmedchem.0c01627, doi:10.1021/acs.jmedchem.0c01627. This article has 72 citations and is from a highest quality peer-reviewed journal.
(umar2025lipoproteinsignalpeptide pages 5-8): Muhammad Umar, Haroon Afzal, Asad Murtaza, and Li-Ting Cheng. Lipoprotein signal peptide as adjuvants: leveraging lipobox-driven tlr2 activation in modern vaccine design. Vaccines, 13:36, Jan 2025. URL: https://doi.org/10.3390/vaccines13010036, doi:10.3390/vaccines13010036. This article has 8 citations.
(kaur2020tlr2agonisticsmall pages 38-39): Arshpreet Kaur, Deepender Kaushik, Sakshi Piplani, Surinder K. Mehta, Nikolai Petrovsky, and Deepak B. Salunke. Tlr2 agonistic small molecules: detailed structure-activity relationship, applications, and future prospects. Journal of medicinal chemistry, 64:233-278, Dec 2021. URL: https://doi.org/10.1021/acs.jmedchem.0c01627, doi:10.1021/acs.jmedchem.0c01627. This article has 72 citations and is from a highest quality peer-reviewed journal.
(sameer2021tolllikereceptors(tlrs) pages 2-3): Aga Syed Sameer and Saniya Nissar. Toll-like receptors (tlrs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. BioMed Research International, Sep 2021. URL: https://doi.org/10.1155/2021/1157023, doi:10.1155/2021/1157023. This article has 517 citations.
(jin2023regulationoftolllike pages 3-4): Mei Jin, Jian Fang, Jiao-jiao Wang, Xin Shao, Suo-wen Xu, Pei-qing Liu, Wen-cai Ye, and Zhi-ping Liu. Regulation of toll-like receptor (tlr) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. Acta Pharmacologica Sinica, 44:2358-2375, Aug 2023. URL: https://doi.org/10.1038/s41401-023-01123-5, doi:10.1038/s41401-023-01123-5. This article has 110 citations and is from a peer-reviewed journal.
(behzadi2021tolllikereceptorsgeneral pages 5-5): Payam Behzadi, Herney Andrés García-Perdomo, and Tomasz M. Karpiński. Toll-like receptors: general molecular and structural biology. Journal of Immunology Research, 2021:1-21, May 2021. URL: https://doi.org/10.1155/2021/9914854, doi:10.1155/2021/9914854. This article has 333 citations and is from a peer-reviewed journal.
(liu2021tolllikereceptorsregulate pages 3-4): Minghui Liu and Ke Zen. Toll-like receptors regulate the development and progression of renal diseases. Kidney Diseases, 7:14-23, Dec 2021. URL: https://doi.org/10.1159/000511947, doi:10.1159/000511947. This article has 55 citations and is from a peer-reviewed journal.
(duan2022tolllikereceptorsignaling pages 2-3): Tianhao Duan, Yang Du, Changsheng Xing, Helen Y. Wang, and Rong-Fu Wang. Toll-like receptor signaling and its role in cell-mediated immunity. Frontiers in Immunology, Mar 2022. URL: https://doi.org/10.3389/fimmu.2022.812774, doi:10.3389/fimmu.2022.812774. This article has 1297 citations and is from a peer-reviewed journal.
(duan2022tolllikereceptorsignaling pages 3-4): Tianhao Duan, Yang Du, Changsheng Xing, Helen Y. Wang, and Rong-Fu Wang. Toll-like receptor signaling and its role in cell-mediated immunity. Frontiers in Immunology, Mar 2022. URL: https://doi.org/10.3389/fimmu.2022.812774, doi:10.3389/fimmu.2022.812774. This article has 1297 citations and is from a peer-reviewed journal.
(sameer2021tolllikereceptors(tlrs) pages 5-6): Aga Syed Sameer and Saniya Nissar. Toll-like receptors (tlrs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. BioMed Research International, Sep 2021. URL: https://doi.org/10.1155/2021/1157023, doi:10.1155/2021/1157023. This article has 517 citations.
(dhakad2025toll‐likereceptorexpression pages 8-8): Prashant K. Dhakad, Raghav Mishra, and Isha Mishra. Toll‐like receptor expression during inflammatory processes in human diseases. Rheumatology & Autoimmunity, Feb 2025. URL: https://doi.org/10.1002/rai2.12167, doi:10.1002/rai2.12167. This article has 6 citations.
(colleselli2023anupdateon pages 6-7): Katrin Colleselli, Anna Stierschneider, and Christoph Wiesner. An update on toll-like receptor 2, its function and dimerization in pro- and anti-inflammatory processes. International Journal of Molecular Sciences, 24:12464, Aug 2023. URL: https://doi.org/10.3390/ijms241512464, doi:10.3390/ijms241512464. This article has 110 citations.
(behzadi2021tolllikereceptorsgeneral pages 12-13): Payam Behzadi, Herney Andrés García-Perdomo, and Tomasz M. Karpiński. Toll-like receptors: general molecular and structural biology. Journal of Immunology Research, 2021:1-21, May 2021. URL: https://doi.org/10.1155/2021/9914854, doi:10.1155/2021/9914854. This article has 333 citations and is from a peer-reviewed journal.
(sameer2021tolllikereceptors(tlrs) pages 3-5): Aga Syed Sameer and Saniya Nissar. Toll-like receptors (tlrs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. BioMed Research International, Sep 2021. URL: https://doi.org/10.1155/2021/1157023, doi:10.1155/2021/1157023. This article has 517 citations.
(xia2021researchprogresson pages 2-4): Pengpeng Xia, Yunping Wu, Siqi Lian, Li Yan, Xia Meng, Qiangde Duan, and Guoqiang Zhu. Research progress on toll-like receptor signal transduction and its roles in antimicrobial immune responses. Applied Microbiology and Biotechnology, 105:5341-5355, Jun 2021. URL: https://doi.org/10.1007/s00253-021-11406-8, doi:10.1007/s00253-021-11406-8. This article has 95 citations and is from a domain leading peer-reviewed journal.
(xia2021researchprogresson pages 4-5): Pengpeng Xia, Yunping Wu, Siqi Lian, Li Yan, Xia Meng, Qiangde Duan, and Guoqiang Zhu. Research progress on toll-like receptor signal transduction and its roles in antimicrobial immune responses. Applied Microbiology and Biotechnology, 105:5341-5355, Jun 2021. URL: https://doi.org/10.1007/s00253-021-11406-8, doi:10.1007/s00253-021-11406-8. This article has 95 citations and is from a domain leading peer-reviewed journal.
(xia2021researchprogresson pages 2-2): Pengpeng Xia, Yunping Wu, Siqi Lian, Li Yan, Xia Meng, Qiangde Duan, and Guoqiang Zhu. Research progress on toll-like receptor signal transduction and its roles in antimicrobial immune responses. Applied Microbiology and Biotechnology, 105:5341-5355, Jun 2021. URL: https://doi.org/10.1007/s00253-021-11406-8, doi:10.1007/s00253-021-11406-8. This article has 95 citations and is from a domain leading peer-reviewed journal.
(kaur2020tlr2agonisticsmall pages 2-4): Arshpreet Kaur, Deepender Kaushik, Sakshi Piplani, Surinder K. Mehta, Nikolai Petrovsky, and Deepak B. Salunke. Tlr2 agonistic small molecules: detailed structure-activity relationship, applications, and future prospects. Journal of medicinal chemistry, 64:233-278, Dec 2021. URL: https://doi.org/10.1021/acs.jmedchem.0c01627, doi:10.1021/acs.jmedchem.0c01627. This article has 72 citations and is from a highest quality peer-reviewed journal.
(behzadi2021tolllikereceptorsgeneral pages 10-12): Payam Behzadi, Herney Andrés García-Perdomo, and Tomasz M. Karpiński. Toll-like receptors: general molecular and structural biology. Journal of Immunology Research, 2021:1-21, May 2021. URL: https://doi.org/10.1155/2021/9914854, doi:10.1155/2021/9914854. This article has 333 citations and is from a peer-reviewed journal.
(dhakad2025toll‐likereceptorexpression pages 5-6): Prashant K. Dhakad, Raghav Mishra, and Isha Mishra. Toll‐like receptor expression during inflammatory processes in human diseases. Rheumatology & Autoimmunity, Feb 2025. URL: https://doi.org/10.1002/rai2.12167, doi:10.1002/rai2.12167. This article has 6 citations.
(xia2021researchprogresson pages 8-9): Pengpeng Xia, Yunping Wu, Siqi Lian, Li Yan, Xia Meng, Qiangde Duan, and Guoqiang Zhu. Research progress on toll-like receptor signal transduction and its roles in antimicrobial immune responses. Applied Microbiology and Biotechnology, 105:5341-5355, Jun 2021. URL: https://doi.org/10.1007/s00253-021-11406-8, doi:10.1007/s00253-021-11406-8. This article has 95 citations and is from a domain leading peer-reviewed journal.
(styczen2025theroleof pages 10-12): Agnieszka Styczeń, Martyna Krysa, Paulina Mertowska, Ewelina Grywalska, Tomasz Urbanowicz, Maciej Krasiński, Malwina Grobelna, Weronika Topyła-Putowska, Mansur Rahnama-Hezavah, and Michał Tomaszewski. The role of toll-like receptors and viral infections in the pathogenesis and progression of pulmonary arterial hypertension—a narrative review. International Journal of Molecular Sciences, 26:11143, Nov 2025. URL: https://doi.org/10.3390/ijms262211143, doi:10.3390/ijms262211143. This article has 6 citations.
(duan2022tolllikereceptorsignaling pages 10-11): Tianhao Duan, Yang Du, Changsheng Xing, Helen Y. Wang, and Rong-Fu Wang. Toll-like receptor signaling and its role in cell-mediated immunity. Frontiers in Immunology, Mar 2022. URL: https://doi.org/10.3389/fimmu.2022.812774, doi:10.3389/fimmu.2022.812774. This article has 1297 citations and is from a peer-reviewed journal.
(dhakad2025toll‐likereceptorexpression pages 10-10): Prashant K. Dhakad, Raghav Mishra, and Isha Mishra. Toll‐like receptor expression during inflammatory processes in human diseases. Rheumatology & Autoimmunity, Feb 2025. URL: https://doi.org/10.1002/rai2.12167, doi:10.1002/rai2.12167. This article has 6 citations.
(kaur2020tlr2agonisticsmall pages 6-8): Arshpreet Kaur, Deepender Kaushik, Sakshi Piplani, Surinder K. Mehta, Nikolai Petrovsky, and Deepak B. Salunke. Tlr2 agonistic small molecules: detailed structure-activity relationship, applications, and future prospects. Journal of medicinal chemistry, 64:233-278, Dec 2021. URL: https://doi.org/10.1021/acs.jmedchem.0c01627, doi:10.1021/acs.jmedchem.0c01627. This article has 72 citations and is from a highest quality peer-reviewed journal.